Article Text

PDF

Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis.
  1. D R Swinson,
  2. J Zlosnick,
  3. L Jackson

    Abstract

    Dapsone given over 14 weeks in a dose of 50 mg a day for 1 week and thereafter 100 mg a day was found to have a beneficial effect in rheumatoid arthritis when compared with placebo administration to a matched group of patients. Significant improvement in 5 out of 7 clinical measurements and in erythrocyte sedimentation rate, viscosity, C-reactive protein was found in those patients taking dapsone. There was significant improvement compared to the placebo group in 2 out of the 7 clinical measurements and again in all 3 acute-phase reactants. The drug was quite well tolerated over the 14-week duration of the trial. The tendency to cause haemolysis will be its main limiting factor as a practical alternative to other suppressive agents currently in use.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.